Cargando…

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data

A COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) has recently been authorized for adolescents in the US. However, the impact of adverse events on adolescents after vaccination has not been fully investigated. To assess the safety of the COVID-19 vaccine in adolescents, the incidence of adverse events (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chae Won, Sa, Soonok, Hong, Myunghee, Kim, Jihyun, Shim, Sung Ryul, Han, Hyun Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143867/
https://www.ncbi.nlm.nih.gov/pubmed/35632500
http://dx.doi.org/10.3390/vaccines10050744
_version_ 1784715910954614784
author Lee, Chae Won
Sa, Soonok
Hong, Myunghee
Kim, Jihyun
Shim, Sung Ryul
Han, Hyun Wook
author_facet Lee, Chae Won
Sa, Soonok
Hong, Myunghee
Kim, Jihyun
Shim, Sung Ryul
Han, Hyun Wook
author_sort Lee, Chae Won
collection PubMed
description A COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) has recently been authorized for adolescents in the US. However, the impact of adverse events on adolescents after vaccination has not been fully investigated. To assess the safety of the COVID-19 vaccine in adolescents, the incidence of adverse events (AEs) in adolescents and adults was compared after vaccination. We included 6304 adolescents (68.14 per 100,000 people) who reported adverse events using vaccine adverse event reporting system (VAERS) data from 10 May 2021 to 30 September 2021. The mean age was 13.6 ± 1.1 years and women (52.7%) outnumbered men. We analyzed severe and common adverse events in response to the COVID-19 vaccine among 6304 adolescents (68.14 per 100,000 people; 52% female; mean age, 13.6 ± 1.1 years). The risk of myocarditis or pericarditis among adolescents was significantly higher in men than in women (OR = 6.61, 95% CI = 4.43 to 9.88; p < 0.001), with a higher frequency after the second dose of the vaccine (OR = 8.52, 95% CI = 5.79 to 12.54; p < 0.001). In addition, severe adverse events such as multisystem inflammatory syndromes, where the incidence rate per 100,000 people was 0.11 (n = 10), and the relative risk was 244.3 (95% CI = 31.27 to 1908.38; p < 0.001), were significantly higher in adolescents than in adults. The risk of the inflammatory response to the COVID-19 vaccine, including myocarditis, pericarditis, or multisystem inflammatory syndromes, was significantly higher in men than in women, with a higher frequency in adolescents than in adults. The inflammation-related AEs may require close monitoring and management in adolescents.
format Online
Article
Text
id pubmed-9143867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91438672022-05-29 Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data Lee, Chae Won Sa, Soonok Hong, Myunghee Kim, Jihyun Shim, Sung Ryul Han, Hyun Wook Vaccines (Basel) Article A COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) has recently been authorized for adolescents in the US. However, the impact of adverse events on adolescents after vaccination has not been fully investigated. To assess the safety of the COVID-19 vaccine in adolescents, the incidence of adverse events (AEs) in adolescents and adults was compared after vaccination. We included 6304 adolescents (68.14 per 100,000 people) who reported adverse events using vaccine adverse event reporting system (VAERS) data from 10 May 2021 to 30 September 2021. The mean age was 13.6 ± 1.1 years and women (52.7%) outnumbered men. We analyzed severe and common adverse events in response to the COVID-19 vaccine among 6304 adolescents (68.14 per 100,000 people; 52% female; mean age, 13.6 ± 1.1 years). The risk of myocarditis or pericarditis among adolescents was significantly higher in men than in women (OR = 6.61, 95% CI = 4.43 to 9.88; p < 0.001), with a higher frequency after the second dose of the vaccine (OR = 8.52, 95% CI = 5.79 to 12.54; p < 0.001). In addition, severe adverse events such as multisystem inflammatory syndromes, where the incidence rate per 100,000 people was 0.11 (n = 10), and the relative risk was 244.3 (95% CI = 31.27 to 1908.38; p < 0.001), were significantly higher in adolescents than in adults. The risk of the inflammatory response to the COVID-19 vaccine, including myocarditis, pericarditis, or multisystem inflammatory syndromes, was significantly higher in men than in women, with a higher frequency in adolescents than in adults. The inflammation-related AEs may require close monitoring and management in adolescents. MDPI 2022-05-09 /pmc/articles/PMC9143867/ /pubmed/35632500 http://dx.doi.org/10.3390/vaccines10050744 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Chae Won
Sa, Soonok
Hong, Myunghee
Kim, Jihyun
Shim, Sung Ryul
Han, Hyun Wook
Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title_full Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title_fullStr Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title_full_unstemmed Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title_short Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
title_sort adverse events and safety profile of the covid-19 vaccines in adolescents: safety monitoring for adverse events using real-world data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143867/
https://www.ncbi.nlm.nih.gov/pubmed/35632500
http://dx.doi.org/10.3390/vaccines10050744
work_keys_str_mv AT leechaewon adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata
AT sasoonok adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata
AT hongmyunghee adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata
AT kimjihyun adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata
AT shimsungryul adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata
AT hanhyunwook adverseeventsandsafetyprofileofthecovid19vaccinesinadolescentssafetymonitoringforadverseeventsusingrealworlddata